Physician profile
Darrell W Plumage
NPI 1013938844
$5,779.26
in general payments reported to CMS, 2019-2025
29 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $177 · 2021: $167 · 2022: $511 · 2023: $1,663 · 2024: $1,346 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,090 · Consulting Fee: $60.00 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,090.19 |
| Consulting Fee | $60.00 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $730.38 | 2019-2025 | Mounjaro, Zepbound, Basaglar |
| Pfizer INC. | $680.25 | 2022-2025 | |
| Amgen INC. | $667.06 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $591.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $500.64 | 2022-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $373.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $341.77 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.84 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $286.31 | 2023-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $185.03 | 2022-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $153.51 | 2019-2025 | |
| Medtronic, INC. | $113.33 | 2024-2025 | Minimed 780g |
| Exact Sciences Corporation | $110.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $98.93 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $94.84 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $90.71 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $72.48 | 2019-2024 | Farxiga |
| Abbvie INC. | $62.87 | 2025 | |
| Mylan Specialty L.P. | $57.87 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.32 | 2022-2023 | |
| Philips North America LLC | $37.99 | 2019 | |
| Grifols USA, LLC | $35.05 | 2019 | |
| Merck Sharp & Dohme LLC | $31.34 | 2020-2025 | Vaxneuvance, M-M-R II, Enflonsia |
| Boston Scientific Corporation | $30.86 | 2024 | Watchman Flx |
| Alexion Pharmaceuticals, INC. | $22.56 | 2022 | |
| Inspire Medical Systems, INC. | $19.52 | 2025 | Inspire |
| Dexcom, INC. | $18.31 | 2025 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $13.62 | 2025 | Uptravi, Opsumit |
| Solventum Corporation | $13.59 | 2024 | V.A.C.Ulta, Prevena, V.A.C. Dermatac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Plumage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.